Kontigo Care Q3 2024: Positive but complex outlook - Redeye
Redeye reiterates its valuation following the Q3 2024 report, which showed slight positive deviations from expectations in absolute numbers. The outlook remains positive yet complex, marked by promising initiatives and ongoing challenges. We believe Kontigo is well-positioned for gradual and international expansion with both its e-health platform (Previct) and its mobile-based drug screening tool (Previct Safety), but it is still some time before these gains fully materialise in the P&L. Overall, we view the case as intact.
Länk till analysen i sin helhet: https://www.redeye.se/research/1049843/kontigo-care-q3-2024-positive-but-complex-outlook?utm_source=finwire&utm_medium=RSS
